An additional study on PLX51107 investigated its use in MYC-driven lymphomas, namely, DLBCL, and found that PLX51107 drove both MYC downregulation in DLBCL cells and BIM-dependent apoptosis that promotes synergy with venetoclax (Bcl-2 inhibitor).280 Success of PLX51107 in preclinical studies have pushed it into a phase I clinical trial that is currently ongoing to evaluate safety, PK, pharmacodynamics, and clinical activity in combination with azacitidine AML and MDS patients. Here, BCL2 is linked to diffuse large B-cell lymphoma.